MELA Sciences
Irvington
About MELA Sciences
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technologies that assist physicians during the clinical evaluation and detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Total funding: $57.0M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jan 2015)
- Ticker: nasdaq:MELA
- Website: melasciences.com
- Phone: (914) 591-3783
Industries & Categories
Health Care, Medical Device, Product Design
Social Profiles
Canonical: https://fsome.com/organization/mela-sciences-2107921 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.